From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine

Gliomas are notoriously aggressive, malignant brain tumors that have variable response to treatment. These patients often have poor prognosis, informed primarily by histopathology. Mathematical neuro-oncology (MNO) is a young and burgeoning field that leverages mathematical models to predict and quantify response to therapies. These mathematical models can form the basis of modern “precision medicine” approaches to tailor therapy in a patient-specific manner. Patient-specific models (PSMs) can be used to overcome imaging limitations, improve prognostic predictions, stratify patients, and assess treatment response in silico. The information gleaned from such models can aid in the construction and efficacy of clinical trials and treatment protocols, accelerating the pace of clinical research in the war on cancer. This review focuses on the growing translation of PSM to clinical neuro-oncology. It will also provide a forward-looking view on a new era of patient-specific MNO.

[1]  G Powathil,et al.  Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy , 2007, Physics in medicine and biology.

[2]  C. Daumas-Duport,et al.  Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities , 2010, Neurology.

[3]  P. Maini,et al.  Mathematical oncology: Cancer summed up , 2003, Nature.

[4]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[5]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Kristin R. Swanson,et al.  Quantifying glioma cell growth and invasion in vitro , 2008, Math. Comput. Model..

[7]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[8]  R. Stupp,et al.  High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Gjedde,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[10]  E. Eisenhauer,et al.  RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.

[11]  Hervé Delingette,et al.  Realistic simulation of the 3-D growth of brain tumors in MR images coupling diffusion with biomechanical deformation , 2005, IEEE Transactions on Medical Imaging.

[12]  V P Antipas,et al.  A four-dimensional computer simulation model of the in vivo response to radiotherapy of glioblastoma multiforme: studies on the effect of clonogenic cell density. , 2006, The British journal of radiology.

[13]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[14]  Gargi Chakraborty,et al.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.

[15]  K. Swanson,et al.  A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.

[16]  J. Murray,et al.  Quantifying Efficacy of Chemotherapy of Brain Tumors with Homogeneous and Heterogeneous Drug Delivery , 2002, Acta biotheoretica.

[17]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[18]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[19]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[21]  Peter Canoll,et al.  Magnetic Resonance Imaging Characteristics of Glioblastoma Multiforme: Implications for Understanding Glioma Ontogeny , 2010, Neurosurgery.

[22]  Luc Taillandier,et al.  Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm , 2008, Neurosurgical Review.

[23]  M Phillips,et al.  Adaptive IMRT using a multiobjective evolutionary algorithm integrated with a diffusion–invasion model of glioblastoma , 2012, Physics in medicine and biology.

[24]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[25]  Alexander R A Anderson,et al.  Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: in Silico Modeling Integrates Imaging and Histology Nih Public Access Author Manuscript Introduction , 2011 .

[26]  Albert Lai,et al.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.

[27]  K. Schaller,et al.  'Go or grow': the key to the emergence of invasion in tumour progression? , 2012, Mathematical medicine and biology : a journal of the IMA.

[28]  Dinggang Shen,et al.  Non-diffeomorphic registration of brain tumor images by simulating tissue loss and tumor growth , 2009, NeuroImage.

[29]  Roy C. P. Kerckhoffs,et al.  Current progress in patient-specific modeling , 2010, Briefings Bioinform..

[30]  Philip Hahnfeldt,et al.  Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .

[31]  R. Fisher.  THE WAVE OF ADVANCE OF ADVANTAGEOUS GENES , 1937 .

[32]  Kristin R. Swanson,et al.  The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.

[33]  Paul E Kinahan,et al.  Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images. , 2011, Mathematical medicine and biology : a journal of the IMA.

[34]  Philip Gerlee,et al.  The Impact of Phenotypic Switching on Glioblastoma Growth and Invasion , 2012, PLoS Comput. Biol..

[35]  R. Guillevin,et al.  Simulation of anisotropic growth of low‐grade gliomas using diffusion tensor imaging , 2005, Magnetic resonance in medicine.

[36]  J. Honnorat,et al.  Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas , 2010, Journal of Neuro-Oncology.

[37]  A R Padhani,et al.  The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. , 2001, The British journal of radiology.

[38]  P. LaViolette,et al.  Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas , 2011, Journal of Neuro-Oncology.

[39]  Alan C. Evans,et al.  A fully automatic and robust brain MRI tissue classification method , 2003, Medical Image Anal..

[40]  J. Rees.  Neuro-oncology , 2010, Practical Neurology.

[41]  J. Murray,et al.  Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.

[42]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Nishikawa.  Standard therapy for glioblastoma--a review of where we are. , 2010, Neurologia medico-chirurgica.

[44]  Philip Hahnfeldt,et al.  Quantitative Modeling of Tumor Dynamics and Radiotherapy , 2010, Acta biotheoretica.

[45]  J Koivukangas,et al.  Computer modeling of brain tumor growth. , 2008, Mini reviews in medicinal chemistry.

[46]  A. Padhani,et al.  The RECIST criteria: implications for diagnostic radiologists , 2001 .

[47]  Benjamin M Ellingson,et al.  Spatially quantifying microscopic tumor invasion and proliferation using a voxel‐wise solution to a glioma growth model and serial diffusion MRI , 2011, Magnetic resonance in medicine.

[48]  Bradley J Erickson,et al.  Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. , 2006, Neuro-oncology.

[49]  K. Swanson,et al.  A mathematical model for brain tumor response to radiation therapy , 2009, Journal of mathematical biology.

[50]  Hervé Delingette,et al.  Image Guided Personalization of Reaction-Diffusion Type Tumor Growth Models Using Modified Anisotropic Eikonal Equations , 2010, IEEE Transactions on Medical Imaging.

[51]  S. Kramer,et al.  The extent of intracranial gliomata at autopsy and its relationship to techniques used in radiation therapy of brain tumors. , 1960, The American journal of roentgenology, radium therapy, and nuclear medicine.

[52]  Kristin R. Swanson,et al.  Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric , 2013, PloS one.

[53]  Georgios S. Stamatakos,et al.  A detailed numerical treatment of the boundary conditions imposed by the skull on a diffusion-reaction model of glioma tumor growth. Clinical validation aspects , 2012, Appl. Math. Comput..

[54]  J M Wardlaw,et al.  Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[55]  N. Rashevsky,et al.  Mathematical biology , 1961, Connecticut medicine.

[56]  Barbara J Fisher,et al.  Effects of radiation on a three-dimensional model of malignant glioma invasion , 1999, International Journal of Developmental Neuroscience.

[57]  Luc Taillandier,et al.  Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas , 2006, Annals of neurology.

[58]  W. Cavenee,et al.  Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.